Quality by Design in the CMO Environment - - BioPharm International

ADVERTISEMENT

Quality by Design in the CMO Environment


BioPharm International
Volume 20, Issue 12

Susan Cook is a scientist I, Katherine A. Patton is a scientist I, and L. Rochelle Bazemore, PhD, is a staff scientist, all at Diosynth Biotechnology, NC, 919.388.5700,

REFERENCES

1. Juran J. Quality by Design. Mankato, MN: The Free Press; 1992.

2. US Food and Drug Administration. Guidance for industry: Q8 pharmaceutical development. Rockville, MD; 2006 May.

3. US FDA. Guidance for Industry: PAT—a framework for innovative pharmaceutical development, manufacturing, and quality assurance. Rockville, MD; 2004 Sept.

4. The PAT Team and Manufacturing Science Working Group. Innovation and continuous improvement in pharmaceutical manufacturing—Pharmaceutical cGMPs for the 21st century. Rockville, MD; Aug 2002.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here